The GLP is committed to full transparency. Download and review our 2019 Annual Report

Viewpoint: Glyphosate herbicide’s ‘tough year’ could get much worse

| | October 9, 2017
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Monsanto’s flagship weed killer, Roundup, has had a tough year. And it could get worse.

With Roundup at the center of a federal case in the United States over claims that it causes cancer, European Union officials … weigh whether to allow the continued use of products that contain Roundup’s active ingredient, glyphosate, in its 28 nations.

Because Europe makes such decisions the way Americans vote for president — with a weighted vote among its member states — the outcome is tricky to predict.

A final decision, already long delayed, is not expected until later this year. France and Italy have indicated they will oppose the reauthorization, while Germany’s position remains unclear. A range of outcomes are possible, including phasing out Roundup and similar products entirely or limiting the length of their reapproval.

Related article:  Global scientists assess homeopathy-funded Séralini study claiming all GMO tests 'contaminated'

While Roundup still enjoys broad support among farmers and a number of European governments, sentiment against its maker is at a low point in Europe, with a petition campaign against glyphosate reportedly surpassing one million signatures.

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion and analysis. Read full, original post: Monsanto’s Roundup Faces European Politics and U.S. Lawsuits


News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend